Simcere Pharmaceutical Group Investor Relations

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients and its property management business. The company was founded in 1995 and is headquartered in Nanjing, China.

Read Less